Fortress Biotech, Inc. (FBIO)
2.135
+0.04
(+2.15%)
USD |
NASDAQ |
Oct 09, 16:00
2.135
0.00 (0.00%)
After-Hours: 20:00
Fortress Biotech Cash from Operations (Quarterly) : -59.28M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -59.28M |
| March 31, 2026 | 203.85M |
| December 31, 2025 | -18.10M |
| September 30, 2025 | -6.11M |
| June 30, 2025 | -27.56M |
| March 31, 2025 | -19.56M |
| December 31, 2024 | 38.09M |
| September 30, 2024 | -71.06M |
| June 30, 2024 | -21.84M |
| March 31, 2024 | -25.39M |
| December 31, 2023 | -34.94M |
| September 30, 2023 | -16.78M |
| June 30, 2023 | -33.29M |
| March 31, 2023 | -43.22M |
| December 31, 2022 | -47.84M |
| September 30, 2022 | -43.39M |
| June 30, 2022 | -41.42M |
| March 31, 2022 | -46.86M |
| December 31, 2021 | -36.60M |
| September 30, 2021 | -22.20M |
| June 30, 2021 | -36.05M |
| March 31, 2021 | -21.69M |
| December 31, 2020 | -20.49M |
| September 30, 2020 | -23.89M |
| June 30, 2020 | -17.41M |
| Date | Value |
|---|---|
| March 31, 2020 | -21.89M |
| December 31, 2019 | -25.05M |
| September 30, 2019 | -16.26M |
| June 30, 2019 | -28.32M |
| March 31, 2019 | -25.32M |
| December 31, 2018 | |
| September 30, 2018 | -24.76M |
| June 30, 2018 | -24.08M |
| March 31, 2018 | -27.84M |
| December 31, 2017 | -24.59M |
| September 30, 2017 | -26.90M |
| June 30, 2017 | -21.69M |
| March 31, 2017 | -12.63M |
| December 31, 2016 | -17.79M |
| September 30, 2016 | -8.823M |
| June 30, 2016 | -7.382M |
| March 31, 2016 | -11.64M |
| December 31, 2015 | 2.861M |
| September 30, 2015 | -6.537M |
| June 30, 2015 | -7.868M |
| March 31, 2015 | -8.834M |
| December 31, 2014 | -3.527M |
| September 30, 2014 | -2.321M |
| June 30, 2014 | -4.014M |
| March 31, 2014 | -6.074M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Kura Oncology, Inc. | -62.55M |
| Spero Therapeutics, Inc. | -5.355M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.079M |
| Cash from Financing (Quarterly) | 0.091M |
| Free Cash Flow | 120.28M |
| Free Cash Flow Per Share (Quarterly) | -1.867 |
| Free Cash Flow to Equity (Quarterly) | -59.04M |
| Free Cash Flow to Firm (Quarterly) | -58.39M |
| Free Cash Flow Yield | 167.3% |